Literature DB >> 31820331

Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic.

Yang Lo1, Hsien-Yi Chiu2, Tsen-Fang Tsai3.   

Abstract

BACKGROUND: Erythrodermic psoriasis (EP) is a rare variant of psoriasis that involves more complications and poorer biologic drug survival than plaque-type psoriasis vulgaris (PV). No prior study has explored human leukocyte antigen (HLA) or other genetic polymorphisms in patients with EP.
OBJECTIVES: Our objective was to describe the clinical features, comorbidities, and HLA polymorphisms among Chinese patients with EP.
METHODS: We enrolled consecutive patients with EP from our clinic, with EP defined as generalized confluent erythematous thin plaques covering at least 80% body surface area. Patients were categorized as having primary or secondary EP. Aggravating factors, comorbidities including psoriatic arthritis, family history of psoriasis, age of onset, and treatment history were also identified. Genetic studies were performed for HLA-C and HLA-DRB1, and the results were compared with those from a healthy population and patients with PV.
RESULTS: Of the 63 included patients, the male to female ratio was 2.71:1. Five (7.9%) patients had primary EP, and 58 (92.1%) had secondary EP. Genotyping of HLA-C and HLA-DRB1 was available in 61 and 58 subjects, respectively. HLA-C*0102 was the most frequent HLA-C allele (34.4%), followed by HLA-C*0702 (18.0%). The frequency of HLA-C*0602 allele (4.1%) was lower than in patients with plaque-type psoriasis (4.1 vs. 16.3%, corrected p value [Pc] = 0.02) and similar to that in the healthy population in Taiwan. The most frequent HLA-DRB1 allele was HLA-DRB1*0901 (20.7%), followed by HLA-DRB1*0803 (13.8%). An increased prevalence of psoriatic arthritis (61.9%) and higher male predominance were also noted in comparison with PV.
CONCLUSIONS: There are HLA differences in Chinese patients with EP compared with patients with PV. The incidence of psoriatic arthritis is also higher. The implications of the above findings await further investigation.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31820331     DOI: 10.1007/s40291-019-00441-x

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  63 in total

1.  Prevalence and treatment of psoriasis in the United Kingdom: a population-based study.

Authors:  Joel M Gelfand; Rachel Weinstein; Steven B Porter; Andrea L Neimann; Jesse A Berlin; David J Margolis
Journal:  Arch Dermatol       Date:  2005-12

2.  HLA markers and progression in psoriatic arthritis.

Authors:  D D Gladman; V T Farewell; K A Kopciuk; R J Cook
Journal:  J Rheumatol       Date:  1998-04       Impact factor: 4.666

3.  Power and sample size calculations. A review and computer program.

Authors:  W D Dupont; W D Plummer
Journal:  Control Clin Trials       Date:  1990-04

4.  HLA antigens among Chinese in Taiwan: association of Cw1 and Cw3 on the same haplotype.

Authors:  M Lin-Chu; S J Lin; S L Chang; S J Tsai; T F Yang
Journal:  Hum Hered       Date:  1989       Impact factor: 0.444

5.  Clinical features of psoriatic arthritis in Korean patients with psoriasis: a cross-sectional observational study of 196 patients with psoriasis using psoriatic arthritis screening questionnaires.

Authors:  Dongyun Shin; Hee Joo Kim; Dae Suk Kim; Soo Min Kim; Jin Su Park; Yong-Beom Park; Min-Geol Lee
Journal:  Rheumatol Int       Date:  2015-09-22       Impact factor: 2.631

6.  Clinical analysis of 84 cases of erythrodermic psoriasis and 121 cases of other types of erythroderma from 2010-2015.

Authors:  Ping Zhang; Hong-Xiang Chen; Jian-Jun Xing; Zhao Jin; Feng Hu; Teng-Long Li; Xiao-Yong Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

7.  HLA risk haplotype Cw6,DR7,DQA1*0201 and HLA-Cw6 with reference to the clinical picture of psoriasis vulgaris.

Authors:  I Ikäheimo; A Tiilikainen; J Karvonen; S Silvennoinen-Kassinen
Journal:  Arch Dermatol Res       Date:  1996-06       Impact factor: 3.017

Review 8.  A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects.

Authors:  Ya C Tsai; Tsen F Tsai
Journal:  G Ital Dermatol Venereol       Date:  2016-02-18       Impact factor: 2.011

9.  Comprehensive genotyping in two homogeneous Graves' disease samples reveals major and novel HLA association alleles.

Authors:  Pei-Lung Chen; Cathy Shen-Jang Fann; Chen-Chung Chu; Chien-Ching Chang; Su-Wei Chang; Hsin-Yi Hsieh; Marie Lin; Wei-Shiung Yang; Tien-Chun Chang
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

10.  Epidemiology and Clinical Features of Adult Patients with Psoriasis in Malaysia: 10-Year Review from the Malaysian Psoriasis Registry (2007-2016).

Authors:  Azura Mohd Affandi; Iman Khan; Nooraishah Ngah Saaya
Journal:  Dermatol Res Pract       Date:  2018-04-23
View more
  4 in total

1.  Associations between HLA-Cw1 and Systemic Treatment Response of Asian Psoriasis Patients.

Authors:  Shin-Shin Ho; Tsen-Fang Tsai
Journal:  Mol Diagn Ther       Date:  2022-07-05       Impact factor: 4.476

2.  Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information.

Authors:  Marina Talamonti; Marco Galluzzo
Journal:  Ann Transl Med       Date:  2020-08

3.  TCM Treatment and Drug Co-Occurrence Analysis of Psoriasis.

Authors:  Li Lin; Suqing Yang; Qingsong Bai; Yuepeng An
Journal:  Comput Intell Neurosci       Date:  2022-01-29

Review 4.  Mechanisms and inhibitors of ferroptosis in psoriasis.

Authors:  Qiao Zhou; Lijing Yang; Ting Li; Kaiwen Wang; Xiaobo Huang; Jingfen Shi; Yi Wang
Journal:  Front Mol Biosci       Date:  2022-09-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.